Lindner Center of HOPE

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Lindner Center of HOPE sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).

23 total trials none currently recruiting 18 completed later-stage tilt top decile by trial count

Lindner Center of HOPE: 23 sponsored US clinical trials, none currently recruiting.

Lindner Center of HOPE sponsors 23 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 18 completed. 18 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Panic Disorder, with 1 trials.

Top-decile sponsor footprint

Lindner Center of HOPE ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 35/100

18 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

23 total, page 1 of 1

COMPLETED Phase 2

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

NCT03158805

COMPLETED Phase 2

Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)

NCT02659475

TERMINATED Phase 2

N-acetylcysteine in Bulimia Nervosa

NCT01131572

COMPLETED Phase 3

Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder

NCT01090713

TERMINATED Phase 3

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

NCT01131559

TERMINATED Phase 3

Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression

NCT01093963

TERMINATED Phase 3

N-acetylcysteine in the Treatment of Bulimia Nervosa

NCT01033149

COMPLETED Phase 3

Armodafinil in Binge Eating Disorder (BED)

NCT01010789

COMPLETED Phase 3

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

NCT00363376

TERMINATED Phase 3

Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance

NCT00585208

COMPLETED Phase 2

Sodium Oxybate in the Treatment of Binge Eating Disorder

NCT00514995

COMPLETED Phase 2

Acamprosate in the Treatment of Binge-Eating Disorder

NCT00511940

COMPLETED Phase 3

Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling

NCT00438776

COMPLETED Phase 3

Bipolar II Depression: Lithium, SSRI, or the Combination

NCT00276965

COMPLETED Phase 4

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

NCT00363337

COMPLETED Phase 4

Atomoxetine in the Treatment of Binge Eating Disorder

NCT00327834

COMPLETED Phase 3

Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity

NCT00277641

COMPLETED Phase 3

Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks

NCT00279617

COMPLETED Phase 3

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity

NCT00221442

COMPLETED Phase 3

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

NCT00277667

COMPLETED Phase 3

Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

NCT00277654

COMPLETED Phase 3

Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania

NCT00278772

COMPLETED Phase 3

Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation

NCT00280839

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 16
Phase 4 2

How the Lindner Center of HOPE archive is shaped

23 indexed studies, none listed as recruiting (0% open); 18 completed (78%).

Phase mix: 18 late (III/IV) vs 5 early (I/II) (later-stage heavy).

Top condition: Panic Disorder (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Lindner Center of HOPE: archived-pipeline peers nationwide

Peers matched on 23 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Lindner Center of HOPE sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15%20%25% Total trials Recruiting share Lindner Center of HOPEAMAG PharmaceuticalsAtriCureCara TherapeuticsCraig L Slingluff, Jr10xBio22nd Century Group23andMe3-C Institute for Social Development
Lindner Center of HOPE sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Lindner Center of HOPE sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 23 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Lindner Center of HOPE page

23 registered trials is a research-attention snapshot, not an endorsement of Lindner Center of HOPE or any single study.

  • None of Lindner Center of HOPE's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Panic Disorder is the condition Lindner Center of HOPE studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Panic Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Lindner Center of HOPE pipeline card: 23 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.